Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.58 |
| ▸ | CDK2 | P24941 | 17/20 | 0.58 |
| ▸ | CDK4 | P11802 | 16/20 | 0.58 |
| ▸ | CCND1 | P24385 | 16/20 | 0.58 |
| ▸ | CASK | O14936 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.58 |
| ▸ | STK10 | O94804 | 1/20 | 0.58 |
| ▸ | CDK14 | O94921 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | MAK | P20794 | 1/20 | 0.58 |
| ▸ | CDK11B | P21127 | 1/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | CLK3 | P49761 | 1/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | CDK7 | P50613 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654700 | 0.96 | CDK1 (0.56) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL4350445 | 0.93 | CDK1 (0.50) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL4354397 | 0.92 | CDK1 (0.49) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL4355434 | 0.92 | CDK1 (0.49) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL4348139 | 0.92 | CDK1 (0.57) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL3521768 | 0.91 | CDK2 (0.49) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL4360092 | 0.90 | CDK1 (0.58) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL4355422 | 0.90 | CDK2 (0.58) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL4349012 | 0.89 | CDK1 (0.47) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL5737668 | 0.89 | CDK1 (0.54) | CDK1CDK2CDK4CCND1CASK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463342-B1 | ESTROGEN RECEPTOR MODULATOR COMBINATIONS | UNIV CALIFORNIA (US) | 2023-09-06 | — | — | EP | claimed |
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | claimed |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-09 | — | — | US | claimed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | claimed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-1726953-B1 | Biomarker for response monitoring of CDK inhibitors in the clinic | HOFFMANN LA ROCHE (CH) | 2008-08-20 | — | — | EP | claimed |
| US-7157455-B2 | 4-Aminopyrimidine-5-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-02 | — | — | US | claimed |
| US-20060269482-A1 | Cyclin-dependent kinase inhibition of Rb phosphorylation | DEPINTO WANDA E | 2006-11-30 | — | — | US | claimed |
| EP-1628619-A2 | 4-AMINOPYRIMIDINE-5-ONE | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | claimed |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID JOSEPH (US) | 2004-08-19 | — | — | US | claimed |
| WO-2004069139-A2 | 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | claimed |
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20150269307-A1 | TARGET INHIBITION MAP SYSTEM FOR COMBINATION THERAPY DESIGN AND METHODS OF USING SAME | TEXAS TECH UNIVERSITY SYSTEM | 2015-09-24 | — | — | US | disclosed |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID J | 2006-10-12 | — | — | US | disclosed |
| EP-1628619-A2 | 4-AMINOPYRIMIDINE-5-ONE | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID JOSEPH (US) | 2004-08-19 | — | — | US | disclosed |
| WO-2004069139-A2 | 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK1 4/4885CDK2 27/4885CDK4 8/4885 |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK6 | CDK1 6/4885CDK2 4/4885CDK4 1/4885 |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK1 4/4885CDK2 27/4885CDK4 8/4885 |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK2 | CDK1 6/4885CDK2 3/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.